Agile Therapeutics Inc. (NASDAQ:AGRX) rose 3% during mid-day trading on Thursday . The stock traded as high as $7.46 and last traded at $7.46, with a volume of 144,939 shares traded. The stock had previously closed at $7.24.

AGRX has been the subject of several recent analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $18.00 target price on shares of Agile Therapeutics in a research note on Tuesday, May 10th. FBR & Co reissued a “buy” rating and set a $17.00 target price on shares of Agile Therapeutics in a research note on Tuesday, May 10th. Noble Financial reissued a “buy” rating and set a $15.00 target price on shares of Agile Therapeutics in a research note on Tuesday, August 9th. Finally, Zacks Investment Research cut Agile Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $15.00.

The company has a 50-day moving average of $7.05 and a 200-day moving average of $6.73. The stock’s market capitalization is $214.49 million.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.29). Equities research analysts predict that Agile Therapeutics Inc. will post ($1.26) EPS for the current year.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.